In recent weeks, the global population has been facing a concerning challenge in the form of a novel coronavirus, 2019-nCoV, originating in Wuhan, China. This virus has spread rapidly, leading to confirmed cases in 22 countries and several thousand deaths worldwide. Scientists around the world are racing to find an effective medicine to treat the disease and, ultimately, to put an end to this global health emergency.

Effective treatment for coronavirus infection

One promising solution is the immunomodulator drug baricitinib, which has been used to effectively treat rheumatoid arthritis since 2012. Though the medication has never been tested on humans exposed to 2019-nCoV, studies done in mice infected with this virus have shown that it can reduce inflammation and speed up the recovery process. These results are promising, as similar results have also been seen in previous studies of the agent’s effect when used for other viruses, including influenza.

The Baricitinib lasting effects

In addition to its potential uses for treating 2019-nCoV, baricitinib has several other characteristics that make it an attractive option for treating the virus. First, it is a readily available, oral pill that could be given to an infected person without requiring them to be hospitalized. Second, studies indicate that this drug does not have many side effects, even when taken for long periods of time, which makes it an attractive option for treating a virus that may require long-term treatment. Last, baricitinib has been proven safe and effective in humans, making it an option that physicians are already familiar with and comfortable prescribing.

Strength of its value

Despite its advantages, however, baricitinib still has many drawbacks as a potential treatment for 2019-nCoV. Because it has not yet been tested on any humans infected with the virus, it is impossible to know whether it will be truly effective in treating the virus or have any serious side effects. Additionally, its effect on the virus may be weakened by the fact that it is older technology, meaning that it may not be as effective as some of the newer medications that are currently being tested.

The medicines use

Baricitinib is a medication that is used for the treatment of moderate to severe rheumatoid arthritis (RA). It is the first of a new class of medication known as Janus kinase (JAK) inhibitors. Baricitinib works by blocking the activity of certain chemicals in the body that causes inflammation, thus reducing arthritis-related pain and swelling. It is usually prescribed in combination with other medications such as methotrexate and/or other disease-modifying antirheumatic drugs (DMARDs).

Endurance increases with time

When taken as prescribed, baricitinib has been shown to reduce joint tenderness and swelling, relieve morning stiffness, and improve physical functioning with time. It is thought to be more effective than other DMARDs, such as methotrexate, when it comes to improving overall physical functioning in patients suffering from RA. In addition to relieving RA symptoms, baricitinib can also be used in combination with other therapies to reduce the risk of disease progression.


In this blog, you read about tab baricitinib 2mg uses & side effects. Overall baricitinib has the potential to be an effective treatment for 2019-nCoV. However, more research is still needed to determine whether it is a viable option in terms of safety and effectiveness. If it is, the drug could help to reduce the number of fatalities and recoveries from the virus and put an end to this global health crisis.

Also read about- Beware of the Symptoms of Rheumatoid Arthritis